$24.42
1.45% day before yesterday
Nasdaq, May 30, 09:46 pm CET
ISIN
US7207951036
Symbol
PVLA
Sector
Industry

Pieris Pharmaceuticals, Inc. Stock price

$24.13
-0.15 0.62% 1M
+7.70 46.87% 6M
+12.13 101.08% YTD
+14.34 146.54% 1Y
-114.27 82.57% 3Y
-254.27 91.33% 5Y
-215.87 89.95% 10Y
Nasdaq, Closing price Fri, May 30 2025
-0.65 2.62%
ISIN
US7207951036
Symbol
PVLA
Sector
Industry

Key metrics

Market capitalization $266.77m
Enterprise Value $191.14m
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.79
Free Cash Flow (TTM) Free Cash Flow $-10.61m
Cash position $75.63m
P/E forward negative
Short interest 2.12%

Is Pieris Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Pieris Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast:

Buy
100%

Financial data from Pieris Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.05 0.05
100% 100%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.94 5.94
65% 65%
11,880%
- Research and Development Expense 8.15 8.15
81% 81%
16,300%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -14 -14
11% 11%
-28,190%
Net Profit -17 -17
29% 29%
-34,860%

In millions USD.

Don't miss a Thing! We will send you all news about Pieris Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pieris Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
Ms. Kline to lead Palvella's commercial buildout for planned standalone U.S. launch of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations, a serious, rare, and lifelong genetic disease affecting an estimated more than 30,0000 patients in the U.S., if approved Under Kline's leadership at Dompé, Oxervate®, a first-in-disease topical therapy for rare d...
Neutral
GlobeNewsWire
17 days ago
Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) has exceeded enrollment target of 40 patients; enrollment expected to close in June 2025
Neutral
GlobeNewsWire
24 days ago
WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its first quarter 2025 financial results on ...
More Pieris Pharmaceuticals, Inc. News

Company Profile

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Head office United States
CEO Wesley Kaupinen
Founded 2001
Website palvellatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today